Ogier helps take leading biotech firm Mirxes public in Hong Kong

Ogier's Corporate specialists in Hong Kong acted as Cayman Islands counsel to Singapore-based biotech company, Mirxes Holding Company Limited, on its initial public offering on the Hong Kong Stock Exchange and the international offering in reliance on Regulation S.

Shares in Cayman-incorporated Mirxes Holding Company Limited commenced trading on the Main Board of the Hong Kong Stock Exchange (HKEX) on 23 May 2025. The gross proceeds from the initial public offering (IPO) amounted to approximately HK$1.09 billion, making it the largest medical device listing on the HKEX under Chapter 18A of the Listing Rules since 2022. It is also the first South East Asian biotech company to reach unicorn status on the HKEX.

Mirxes is a micro ribonucleic acid (miRNA) technology company that is making diagnostic solutions for the screening of diseases accessible in key Asian markets, including Singapore and China. It is one of the few companies globally that have obtained regulatory approval for In Vitro Diagnostics (IVD) products in the molecular cancer screening industry.

The Ogier team was led by partner Cecilia Li, with support from the firm's global head of Corporate Nathan Powell, legal managers Jasmine Chan and Kingston Tang and paralegal Josie Ma.

Ogier worked closely with Davis Polk & Wardwell as the company's Hong Kong and US counsel and Jingtian & Gongcheng as the company's PRC counsel.